Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides

IGF-1 LR3

Growth Hormone
Phase 1 Research
35%
Moderate Risk
3/5

Warnings

Potent anabolic - risk of organ growth
Monitor blood glucose
Cancer concern due to cell proliferation

Contraindications

PregnancyBreastfeedingActive CancerDiabetes

Drug Interactions

Insulin

Possible Side Effects

HypoglycemiaJoint PainWater RetentionOrgan Growth

Legal & Regulatory

FDA Status Research Only
WADA Status Prohibited in Sport
Prescription Not Required

Pregnancy

Category X - Contraindicated